Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Complex ANDAs To Be Allowed Pre-Submission Product Meetings

Executive Summary

FDA will be able to give scientific advice and sponsors can familiarize reviewers with upcoming generic applications for complex products under new provision in GDUFA II.

You may also be interested in...



Generic Drug User Fees Will Jump More Than 50% In FY 2018

GDUFA II's fee structure shifts burden from manufacturers to sponsors though 'ANDA holder fee.'

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

GDUFA II gives certain generics the possibility of an even faster review clock, which burnishes FDA's credentials in the drug pricing debate, but in order to take advantage, applications will need to be of high quality in addition to addressing a public health priority.

EpiPen Familiarity May Prove Tough Hurdle For Generics

With EpiPen injector patent-protected and patients accustomed to its use, finding a substitutable generic device may prove difficult.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB001980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel